⌘+K

August 12, 2024Annals of Internal Medicine

Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort

View at Publisher

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

There are currently no validated clinical biomarkers of postacute sequelae of SARS-CoV-2 infection (PASC).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Erlandson et al. (2024) studied this question.

synapsesocial.com/papers/68e5c971b6db64358755fa2f https://doi.org/10.7326/m24-0737

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Early biological markers of post-acute sequelae of SARS-CoV-2 infection2024 · 43 citations
2Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptomsOriginal Research · 2021 · 249 citations
3Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for MeasurementCohort Study · 2021 · 132 citations
4Emerging Biomarkers Across the Clinical Spectrum of SARS-CoV-2 Infection and Long COVIDLiterature Review · 2026
5Early immune factors associated with the development of post-acute sequelae of SARS-CoV-2 infection in hospitalized and non-hospitalized individualsOriginal Research · 2024 · 13 citations

More from Annals of Internal Medicine

More from Stanford University